Factors Associated with Fatal COVID-19 Outcomes among People Living with HIV: A Cohort Study

Curr HIV Res. 2023;21(6):367-377. doi: 10.2174/011570162X277788231128111517.

Abstract

Background: People living with HIV (PLHIV) are at increased risk of COVID-19 death. However, information about whether factors related to the HIV-infection influence the COVID-19 outcome still remains conflicting.

Objective: Here, we evaluate the risk factors for fatal COVID-19 in a cohort of PLHIV from the Moscow region, aged >18 years and diagnosed with COVID-19 between March 2020 and December 2021.

Methods: Demographic, clinical and laboratory data were compared between different COVID-19 outcomes. To analyze the risk factors associated with COVID-19 death, we employed the logistic regression method. A total of 566 PLHIV were included in the analysis.

Results: The majority of individuals, 338 (59.7%), were male; 194 (34.3%) were on antiretroviral therapy; 296 (52.3%) had a comorbidity; 174 (30.7%) of patients had drug and/or alcohol dependence; 160 (33.1%) patients had CD4 counts <200 cells/μl; 253 (51.9%) had undetectable viral load. Our analysis revealed that PLHIV >55 years old (OR, 12.88 [95% CI, 2.32-71.62]), patients with a viral load of more than 1000 copies/ml (OR, 2.45 [95%CI, 1.01-5.98]) and with CD4 counts <200 cell/μl (OR, 2.54 [95%CI, 1.02-6.28]), as well as with a history of cachexia (OR, 3.62 [95%CI, 1.26-10.39]) and pneumocystis pneumonia (OR, 2.47 [95%CI, 1.03-5.92]), and drug/alcohol dependence (OR, 2.70 [95%CI, 1.36-5.39]) were significantly more likely to die from COVID-19.

Conclusion: These data show that people with advanced HIV-1 infection have an increased risk of fatal COVID-19 outcomes and that there is a need to improve this population's access to health services and, hence, increase their survival rates.

Keywords: COVID-19; HIV; co-infection; cohort studies; comorbidity; outcomes; pandemic..

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alcoholism* / complications
  • Anti-HIV Agents* / therapeutic use
  • COVID-19* / complications
  • Cohort Studies
  • Female
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Male
  • Middle Aged

Substances

  • Anti-HIV Agents